Artemisinin-based combination therapy for ... - The Cochrane Library

(... Continued)
Study or subgroup AS+AQ AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 360 161 0.01 [ 0.00, 0.23 ]
Total events: 0 (AS+AQ), 16 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
3 Gametocyte carriage day 7
Faye 2003 SEN 0/360 19/161 0.01 [ 0.00, 0.19 ]
Dorsey 2006 UGA 11/111 13/105 0.80 [ 0.38, 1.71 ]
Menard 2006 MDG 2/80 3/80 0.67 [ 0.11, 3.88 ]
Subtotal (95% CI) 551 346 0.25 [ 0.02, 2.69 ]
Total events: 13 (AS+AQ), 35 (AQ+SP)
Heterogeneity: Tau 2 = 3.61; Chi 2 = 12.43, df = 2 (P = 0.002); I 2 =84%
Test for overall effect: Z = 1.15 (P = 0.25)
4 Gametocyte carriage day 14
Faye 2003 SEN 0/360 0/161 0.0 [ 0.0, 0.0 ]
Dorsey 2006 UGA 7/109 8/105 0.84 [ 0.32, 2.24 ]
Menard 2006 MDG 1/79 5/80 0.20 [ 0.02, 1.69 ]
Subtotal (95% CI) 548 346 0.57 [ 0.16, 2.02 ]
Total events: 8 (AS+AQ), 13 (AQ+SP)
Heterogeneity: Tau 2 = 0.33; Chi 2 = 1.47, df = 1 (P = 0.23); I 2 =32%
Test for overall effect: Z = 0.88 (P = 0.38)
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
0.001 0.01 0.1 1 10 100 1000
Favours ASAQ Favours AQSP
198